POCMA is working with the Media Rating Council to evaluate which existing media standards can apply to point-of-care and where custom definitions are needed. Nicole DeVinagracia says technical subgroups will account for print, digital and EHR formats so any framework is relevant across the channel.
Nicole DeVinagracia says marketers should stop expecting every tactic to perform the same job. She positions TV as a reach vehicle and point-of-care as the channel that turns awareness into education and more informed conversations with healthcare providers. That differentiation should shape how channels are incorporated into media plans.
FDA granted accelerated approval to GSK's Jim Parley for locally advanced rectal cancer after a small Memorial Sloan Kettering study showed every patient had a complete response. The drug could allow some patients to avoid chemotherapy, radiation and life-altering surgery, though GSK still must confirm clinical benefits.
Nicole DeVinagracia says the key principle is to start with a care journey, not a specific media tactic, because point-of-care spans offices, pharmacies, telehealth and EHR platforms. She warns against isolated placements and says touchpoints should connect across the journey. That requires planning early and customizing messages for patients and providers.
Roche expanded its Hansa Pharmaceutical partnership with $400 million upfront and $110 million due on the first anniversary. Hansa will advance multiple antibody-drug conjugates through Phase I before Roche takes over outside Greater China; the deal carries up to $15 billion in milestones. Roche had already struck an ADC deal last year.
Nicole DeVinagracia cites M3MI data showing 70% of patients who noticed doctor's office advertising filled a prescription or took medication as prescribed, versus 55% who did not notice ads. That performance gap helps explain why point-of-care spending surpassed $1.2 billion in 2025, according to POCMA's reported industry figure.
